Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.
- Q1 revenue of $1.2 million from insurer-backed clinical services
- Over 75% PTSD patients show sustained improvement, two-thirds in remission after 12 months
- Victorian clinic launch on track with 31 therapists trained
- Global Partnership Program launched for international drug sponsors
- Cash runway of over seven quarters despite $1.23 million operating outflow
Revenue Growth Supported by Expanding Insurer-Funded Clinics
Emyria Limited (ASX:EMD) posted group revenue of $1.2 million for the March quarter, reflecting steady growth from its insurer-funded Empax clinical services. The ramp-up in patient throughput across its Perth and Brisbane clinics underpins this performance, validating the repeatability of its capital-light, hospital-integrated model. Cash receipts for the quarter were $891,000, while net operating cash outflows of $1.23 million primarily funded workforce expansion and new clinic activations.
The company’s expansion into Victoria is progressing well, with its Mornington Peninsula clinic set to launch in Q2 2026. The site already has 31 contracted and trained therapists and multiple psychiatrists onboarded, supported by secured medication supply and operational agreements. This rollout is underpinned by Medibank funding, extending insurer-backed programs into Australia’s second-largest state and reinforcing the scalability of Emyria’s reimbursement model. This follows earlier announcements detailing the Victorian clinic workforce and funding milestones Victorian Empax Clinic Set to Launch and insurer support Emyria and Medibank Expand Insurer-Backed Mental Health Care.
Strong Clinical Outcomes Bolster Payer Confidence
National Workforce and Geographic Expansion Accelerate
Emyria’s national footprint continues to grow, with over 100 trained therapists and specialist clinicians now part of the Empax network. The company has commenced targeted recruitment in New South Wales, aiming to establish its fourth state-based clinic. NSW represents Australia’s largest addressable patient market, driven by rising psychological injury claims and healthcare costs. The company’s expanding workforce and operational infrastructure position it well to capture this opportunity, building on its successes in Western Australia and Queensland. The NSW recruitment drive builds on prior efforts to scale clinical capacity Emyria Accelerates NSW Expansion.
Global Partnership Program Targets International Drug Sponsors
Post-quarter, Emyria launched its Empax Global Partnership Program, marking a strategic shift from a domestic clinic operator to a global clinical delivery platform. This program enables international drug sponsors and contract research organisations (CROs) to leverage Emyria’s established clinical infrastructure, workforce, and governance systems for complex mental health treatments, including clinical trials and commercial rollouts.
The initiative is timely given recent US Government Executive Orders accelerating research into psychedelic therapies for serious mental illness. Emyria is uniquely positioned as one of the few companies globally combining reimbursed clinical delivery, real-world outcome data, and sponsor-supported services within a single integrated platform. This capability is already generating revenue, supporting programs such as Psyence BioMed’s phase IIB trial for Adjustment Disorder in advanced cancer patients. This development builds on the company’s earlier announcement of its global services platform launch Emyria Launches Global Services Platform.
Financial Position and Outlook
Despite operating cash outflows of $1.23 million driven by growth investments, Emyria ended the quarter with $9 million in cash, providing an estimated funding runway of over seven quarters at current burn rates. The company’s capital-light, high-margin services model is expected to deliver growing operating revenues as clinic utilisation increases and global partnerships expand.
Key near-term catalysts include the Victorian clinic launch, continued ramp-up of Brisbane and Perth utilisation, NSW expansion, and further global sponsor engagements. The evolving regulatory and policy environment, particularly in the US, may accelerate demand for scalable clinical delivery infrastructure for next-generation mental health treatments.
Bottom Line?
Emyria’s dual domestic and international expansion, backed by strong clinical data and government support, positions it at the forefront of scalable psychedelic-assisted therapy delivery.
Questions in the middle?
- How will payer reimbursement evolve as Emyria expands into new states and treatment indications?
- What impact will US government initiatives have on global demand for clinical delivery platforms like Emyria?
- Can Emyria sustain its capital-light model while scaling rapidly across multiple jurisdictions?